163 related articles for article (PubMed ID: 21049090)
1. Evaluation of performance, safety, subject acceptance, and compliance of a disposable autoinjector for subcutaneous injections in healthy volunteers.
Berteau C; Schwarzenbach F; Donazzolo Y; Latreille M; Berube J; Abry H; Cotten J; Feger C; Laurent PE
Patient Prefer Adherence; 2010 Oct; 4():379-88. PubMed ID: 21049090
[TBL] [Abstract][Full Text] [Related]
2. Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover study.
Vermeire S; D'heygere F; Nakad A; Franchimont D; Fontaine F; Louis E; Van Hootegem P; Dewit O; Lambrecht G; Strubbe B; Baert F
Patient Prefer Adherence; 2018; 12():1193-1202. PubMed ID: 30013330
[TBL] [Abstract][Full Text] [Related]
3. Tezepelumab Pharmacokinetics, Safety, and Tolerability After Administration via Vial-and-syringe, Accessorized Prefilled Syringe, or Autoinjector: A Randomized Trial in Healthy Volunteers.
Zheng Y; Abuqayyas L; Megally A; Fuhr R; Sałapa K; Downie J; Colice G
Clin Ther; 2021 Jan; 43(1):142-155.e5. PubMed ID: 33380362
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and tolerability of prefilled syringe and auto-injector presentations of MSB11456: results of a randomized, single-dose study in healthy adults.
Tomaszewska-Kiecana M; Dryja A; Ullmann M; Petit-Frere C; Illes A; Dagres C; Monnet J
Expert Rev Clin Immunol; 2023 Apr; 19(4):447-455. PubMed ID: 36789991
[TBL] [Abstract][Full Text] [Related]
5. Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector in Healthy Subjects.
Struemper H; Murtaugh T; Gilbert J; Barton ME; Fire J; Groark J; Fox NL; Roth D; Gordon D
Clin Pharmacol Drug Dev; 2016 May; 5(3):208-15. PubMed ID: 27163500
[TBL] [Abstract][Full Text] [Related]
6. Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.
Seddighzadeh A; Hung S; Selmaj K; Cui Y; Liu S; Sperling B; Calabresi PA
Expert Opin Drug Deliv; 2014 Nov; 11(11):1713-20. PubMed ID: 25073663
[TBL] [Abstract][Full Text] [Related]
7. Results of a human factors experiment of the usability and patient acceptance of a new autoinjector in patients with rheumatoid arthritis.
Schwarzenbach F; Dao Trong M; Grange L; Laurent PE; Abry H; Cotten J; Granger C
Patient Prefer Adherence; 2014; 8():199-209. PubMed ID: 24627625
[TBL] [Abstract][Full Text] [Related]
8. Comparison between prefilled syringe and autoinjector devices on patient-reported experiences and pharmacokinetics in galcanezumab studies.
Stauffer VL; Sides R; Lanteri-Minet M; Kielbasa W; Jin Y; Selzler KJ; Tepper SJ
Patient Prefer Adherence; 2018; 12():1785-1795. PubMed ID: 30271122
[TBL] [Abstract][Full Text] [Related]
9. A patient care program for adjusting the autoinjector needle depth according to subcutaneous tissue thickness in patients with multiple sclerosis receiving subcutaneous injections of glatiramer acetate.
Masid ML; Ocaña RH; Gil MJ; Ramos MC; Roig ME; Carreño MR; Morales JC; Carrasco ML; Hidalgo LM; Felices AM; Castaño AH; Romero PC; Martinez PF; Sánchez-De la Rosa R
J Neurosci Nurs; 2015 Feb; 47(1):E22-30. PubMed ID: 25225835
[TBL] [Abstract][Full Text] [Related]
10. Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience.
Callis Duffin K; Bukhalo M; Bobonich MA; Shrom D; Zhao F; Kershner JR; Gill A; Pangallo B; Shuler CL; Bagel J
Med Devices (Auckl); 2016; 9():361-369. PubMed ID: 27785115
[TBL] [Abstract][Full Text] [Related]
11. Prefilled pen versus prefilled syringe: a pilot study evaluating two different methods of methotrexate subcutaneous injection in patients with JIA.
Roszkiewicz J; Swacha Z; Smolewska E
Pediatr Rheumatol Online J; 2020 Aug; 18(1):64. PubMed ID: 32787934
[TBL] [Abstract][Full Text] [Related]
12. Factors influencing the patient evaluation of injection experience with the SmartJect autoinjector in rheumatoid arthritis.
Schulze-Koops H; Giacomelli R; Samborski W; Rednic S; Herold M; Yao R; Govoni M; Vastesaeger N; Weng HH
Clin Exp Rheumatol; 2015; 33(2):201-8. PubMed ID: 25664404
[TBL] [Abstract][Full Text] [Related]
13. Comparative Bioavailability of Hydroxyprogesterone Caproate Administered via Intramuscular Injection or Subcutaneous Autoinjector in Healthy Postmenopausal Women: A Randomized, Parallel Group, Open-label Study.
Krop J; Kramer WG
Clin Ther; 2017 Dec; 39(12):2345-2354. PubMed ID: 29191450
[TBL] [Abstract][Full Text] [Related]
14. Phase 3, open-label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A).
Callis Duffin K; Bagel J; Bukhalo M; Mercado Clement IJ; Choi SL; Zhao F; Gill A; Pangallo B; Shuler C; Mallbris L; Jackson K
J Eur Acad Dermatol Venereol; 2017 Jan; 31(1):107-113. PubMed ID: 27500949
[TBL] [Abstract][Full Text] [Related]
15. Comparison of drug delivery with autoinjector versus manual prefilled syringe and between three different autoinjector devices administered in pig thigh.
Hill RL; Wilmot JG; Belluscio BA; Cleary K; Lindisch D; Tucker R; Wilson E; Shukla RB
Med Devices (Auckl); 2016; 9():257-66. PubMed ID: 27536164
[TBL] [Abstract][Full Text] [Related]
16. Comparable Pharmacokinetics, Safety, and Tolerability of Etrolizumab Administered by Prefilled Syringe or Autoinjector in a Randomized Trial in Healthy Volunteers.
Zhang W; Tyrrell H; Ding HT; Pulley J; Boruvka A; Erickson R; Abouhossein M; Ravanello R; Tang MT
Adv Ther; 2021 May; 38(5):2418-2434. PubMed ID: 33778929
[TBL] [Abstract][Full Text] [Related]
17. Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trial.
Kivitz A; Cohen S; Dowd JE; Edwards W; Thakker S; Wellborne FR; Renz CL; Segurado OG
Clin Ther; 2006 Oct; 28(10):1619-29. PubMed ID: 17157117
[TBL] [Abstract][Full Text] [Related]
18. High Tolerability, Favorable Safety, and Subjects' Preference for a Single 200 mg/2 mL Tildrakizumab Injection: A Phase I, Open-Label, Randomized Crossover Trial in Healthy Volunteers.
Kokolakis G; Kreis G; Falqués M; Aparici M; Sondermann W
Dermatol Ther (Heidelb); 2022 Sep; 12(9):2135-2144. PubMed ID: 35984626
[TBL] [Abstract][Full Text] [Related]
19. Advances in Large Volume Subcutaneous Injections: A Pilot Tolerability Study of an Innovative Needle-Free Injection Platform.
Kelley EL; Fernandes A; Pelletier M; Takami EA; Emery C; Dyer B; Jacoski MV; Lozko V; Burgess B; Smith RH
PDA J Pharm Sci Technol; 2022; 76(6):474-484. PubMed ID: 35296562
[TBL] [Abstract][Full Text] [Related]
20. Ease of use of two autoinjectors in patients with multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: results of the randomized, crossover REDEFINE study.
Wray S; Hayward B; Dangond F; Singer B
Expert Opin Drug Deliv; 2018 Feb; 15(2):127-135. PubMed ID: 29206056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
